{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE312nnn/GSE312124/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312124"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"MAPK- driven glioma progression and reprogramming of the tumor-associated immune response","description":"Glioma evolution is associated with disease progression and therapeutic resistance. We recently identified a group of MAPK-driven glioma with CDKN2A homozygous deletion that are low-grade and immune enriched. However, Over time, these tumors can progress to aggressive, higher-grade tumors. While low-grade tumors may be amenable to immunotherapeutic strategies, it is unknown how the tumor and its microenvironment evolve.","dates":{"publication":"2026/07/16"},"accession":"GSE312124","cross_references":{"GSM":["GSM9338107","GSM9338108","GSM9338103","GSM9338104","GSM9338105","GSM9338106","GSM9338099","GSM9338100","GSM9338101","GSM9338102"],"GPL":["24676"],"GSE":["312124"],"taxon":["Homo sapiens"],"PMID":["[42377256]"]}}